StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Recursion Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Recursion Pharmaceuticals's price to sales ratio was 35.0× on Nov 11, 2026, against 52.1× a year earlier. Over the last 5 years it ranged from 21.7× to 279.5×, with a median of 39.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202635.0×−11.1
2025Dec 31, 202546.0×+16.4
2024Dec 31, 202429.7×−15.4
2023Dec 29, 202345.0×−1.7
2022Dec 30, 202246.8×−232.7
2021Dec 31, 2021279.5×–

More Recursion Pharmaceuticals figures

See a number that looks wrong?